Postępy w Kardiologii Interwencyjnej

Abstract

1/2024 vol. 20
Original paper

Long-term outcomes of mechanical thrombectomy in acute ischaemic stroke patients with concomitant malignancy

  1. Department of Neurology, University Hospital, Krakow, Poland
  2. Department of Neurology, Jagiellonian University Medical College, Krakow, Poland
  3. Student Scientific Group in Cerebrovascular Diseases, Jagiellonian University Medical College, Krakow, Poland
  4. Department of Radiology, Jagiellonian University Medical College, Krakow, Poland
Adv Interv Cardiol 2024; 20, 1 (75): 95–102
Online publish date: 2024/03/25
View full text

Introduction:

Patients with cancer (CP) need a different approach to acute ischaemic stroke (AIS) treatment as intravenous thrombolysis (IVT) may be contraindicated. Mechanical thrombectomy (MT) is a treatment of choice for otherwise eligible patients, although the literature on its long-term outcomes in CP is limited.

Aim:

Assessing outcomes of MT-treated AIS patients with concomitant malignancy in a year-long follow-up.

Material and methods:

The study included 593 MT-treated AIS patients admitted in 2019–2021. The group was divided into CP (defined as a diagnosis of malignancy and undergoing/qualified for cancer treatment within previous 5 years) and a control group. The profile of cardiovascular risk factors, stroke severity and discharge, 90-day and 365-day outcomes were compared between the groups.

Results:

CP and controls had a similar profile of cardiovascular risk factors and comparable stroke severity. CP were less frequently treated with IVT (25.7% vs. 59.1%, p < 0.001). There were no differences between the groups in the successful reperfusion rate and occurrence of haemorrhagic complications. Discharge and 90-day outcomes were similar. CP had higher 365-day mortality (48.6% vs. 29.9%, p = 0.024) but the percentage of patients achieving good functional outcome in a year-long observation was comparable.

Conclusions:

Treatment with MT seems beneficial for AIS patients with concomitant malignancy both in short- and long-term observation.

Share
without publication fees